Cannabix Technologies Inc., a UF startup developing the Cannabix Marijuana Breathalyzer for law enforcement and the workplace, has reported that recent testing with Beta 3.0 has shown the identification and first order separation of two key metabolites of ∆9-tetrahydrocannabinol (“THC”), being 11-hydroxy-delta-9-tetrahydrocannabinol and 11-nor-9-carboxy-tetrahydrocannabinol in standards. In addition, scientists have made significant progress towards using lower flow rates that will become important for user groups with poor lung function. Furthermore, engineers have been testing a new breath capture method that can hold THC breath samples in a stable manner for several days.
∆9-tetrahydrocannabinol (“THC”) the main psychoactive component of marijuana is metabolized into 11-nor-9-carboxy-tetrahydrocannabinol at different rates based on route of entry into the body. Smoked THC is converted predominantly to 11-nor-9-carboxy-tetrahydrocannabinol which is then glucuronidated to a water-soluble form that can be detected in body fluids. Ingested THC is metabolized via the hepatic portal circulation to 11-hydroxy-delta-9-tetrahydrocannabinol prior to oxidation to 11-nor-9-carboxy-tetrahydrocannabinol. The Cannabix FAIMS device coupled to real time switchable mass spectrometry is actively being tuned to detect these key molecules and their complex pathways in the body to enable the identification of recency of use.